The Inspirational Quest to Eradicate Cancer

The world-renowned Thoracic Oncologist, Dr. Gerold Bepler, joined I Don’t Care’s Kevin Stevenson for a conversation that was no less than inspirational. Dr. Bepler, President and CEO of the Karmanos Cancer Institute, has a mission; to eradicate cancer. It’s more than a dream for Dr. Bepler; he believes it will be a reality one day.

Dr. Bepler arrived from Germany to the United States in 1983. Following a post-doctoral fellowship at the National Cancer Institute, the starting point for his journey into lung cancer research. This career path took Dr. Bepler through many stops along the way, and in 2010 he joined the Karmanos Cancer Institute.

The mission to eradicate cancer got a boost in 1971 with the National Cancer Act, and Dr. Bepler said there’s tremendous progress towards this goal since that point. “People now diagnosed with cancer have hope,” Dr. Bepler said. “And many of them get cured of the disease and have a good quality of life. That all wouldn’t have been possible without the National Cancer Act.”

Much of the progress made to eradicating cancer at the Karmanos Cancer Institute owes a debt of gratitude to that 50-year-old law for providing necessary funding that makes such research possible.

“The Karmanos Cancer Institute became one of the NCI designated cancer centers,” Dr. Bepler said. “Very quickly, the National Cancer Institute realized just having one cancer institute in Bethesda, Maryland alone wouldn’t be able to achieve that high goal of eradicating cancer. This network established cancer centers throughout the United States.” What started as a couple of centers in the 1970s is now more than 50 comprehensive cancer centers.

The world now possesses many drugs and treatments to treat cancer through the dedication and research of institutes like the Karmanos Center. And some research led to treatments for other diseases. Dr. Bepler mentioned the Karmanos Center developed three of the first FDA-approved AIDS drugs.

More Like This Story:

The Rising Tide of Food Allergens

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

Follow us on social media for the latest updates in B2B!

Image

Latest

medicine
The Art of Recovery: Where Music and Medicine Meet in Patient Care
May 14, 2026

Healthcare today can feel overwhelming—not just for patients, but for the teams caring for them. After a major illness or injury, recovery isn’t handled by one doctor alone; it often involves a whole network of specialists, from physical therapists to nurses to social workers, all trying to help someone regain their independence and quality…

Read More
infant health
From Monitoring to Knowing: How Owlet Is Redefining Infant Health at Retail
May 14, 2026

Baby monitors have long promised parents the ability to see and hear their child from another room. But as connected health devices become more normalized in everyday life, from smartwatches to sleep trackers, parents are beginning to expect more than visibility. They want insight. For Owlet, that shift matters because its wearable monitors track…

Read More
SPD
Unlocking CensisAI²: The Metrics That Matter for Smarter SPD Decisions
May 13, 2026

Sterile processing departments are swimming in data, from workflow automation and supply data to patient outcome and quality metrics. But the real challenge is not collecting more information; it is knowing which metrics actually improve SPD performance, technician education, OR readiness and patient safety. For Censis, a leader in surgical asset management, the focus…

Read More
User-generated content
The New Rules of Discoverability: How User-Generated Content Is Reshaping Search, Trust, and Brand Visibility
May 12, 2026

User-generated content (UGC) is moving from marketing side dish to main course as large language models change how people discover brands, products, creators, and ideas. Customer reviews, forum posts, videos, and community conversations increasingly carry more influence than polished brand copy because they feel more specific, lived-in, and trustworthy. As AI systems learn from…

Read More